CollPlant Biotechnologies Secures European Patent for BioInk
Ticker: CLGN · Form: 6-K · Filed: Jun 4, 2025 · CIK: 1631487
Sentiment: bullish
Topics: patent, biotechnology, 3D printing, intellectual property
TL;DR
CollPlant just got a European patent for its plant-based BioInk, big win for 3D bioprinting!
AI Summary
CollPlant Biotechnologies Ltd. announced on June 4, 2025, that it has been granted a European patent for its "BioInk" technology. This patent covers the use of recombinant human collagen (rhCollagen) produced in plants for 3D bioprinting of tissues and organs. The company's BioInk is designed to improve the biological performance and mechanical properties of printed constructs.
Why It Matters
This patent strengthens CollPlant's intellectual property portfolio in Europe, potentially enhancing its market position and commercialization efforts for its 3D bioprinting solutions.
Risk Assessment
Risk Level: low — This filing is a routine announcement of a granted patent, which is generally positive news with limited immediate downside risk.
Key Players & Entities
- CollPlant Biotechnologies Ltd. (company) — Registrant
- June 4, 2025 (date) — Date of press release
- European patent (patent) — Subject of announcement
- BioInk (technology) — CollPlant's proprietary product
- recombinant human collagen (rhCollagen) (material) — Key component of BioInk
FAQ
What is the specific subject of the European patent granted to CollPlant Biotechnologies?
The European patent covers the use of recombinant human collagen (rhCollagen) produced in plants for 3D bioprinting of tissues and organs.
When was the press release announcing the patent grant issued?
The press release was issued on June 4, 2025.
What is the primary technology mentioned in the patent announcement?
The primary technology is CollPlant's "BioInk".
What type of material is CollPlant's BioInk based on?
CollPlant's BioInk is based on recombinant human collagen (rhCollagen) produced in plants.
What is the intended application of CollPlant's BioInk technology as per the patent?
The intended application is for 3D bioprinting of tissues and organs.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 4, 2025 regarding CollPlant Biotechnologies Ltd (CLGN).